Alectinib shows promise for the treatment of refractory ALK-positive large B-cell lymphoma: a case report
IntroductionAnaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+ LBCL) is rare, accounts for <1% of DLBCL, and is characterized by ALK rearrangement. ALK+ LBCL is a very aggressive disease with a poor prognosis, a high risk of relapse and a poor response to standard chemotherapy treatm...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Frontiers Media S.A.
2026-06-01
|
| Edice: | Frontiers in Oncology |
| Témata: | |
| On-line přístup: | https://www.frontiersin.org/articles/10.3389/fonc.2026.1844016/full |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|